NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

Tuesday, Pfizer Inc PFE released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...

Credit: Getty Images. Abrysvo is expected to be available in the third quarter of 2023. The Food and Drug Administration (FDA) has approved Abrysvo ™ (respiratory syncytial virus vaccine) for the ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of LRTD ...

As Pfizer races to grow the respiratory syncytial virus (RSV) vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, armed with fresh data for Abrysvo in ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age These ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...